Page 149 - MI-2-4

Microbes & Immunity Glioblastoma therapy: Immunotherapy and inhibitors

for patients with advanced, refractory squamous non-small- doi: 10.1093/neuonc/nou307
cell lung cancer (checkmate 063): A phase 2, single-arm 63. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased
trial. Lancet Oncol. 2015;16(3):257-265.
regulatory T-cell fraction amidst a diminished CD4
doi: 10.1016/s1470-2045(15)70054-9 compartment explains cellular immune defects in patients
with malignant glioma. Cancer Res. 2006;66(6):3294-3302.
53. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab
plus Ipilimumab in advanced non-small-cell lung cancer. N doi: 10.1158/0008-5472.can-05-3773
Engl J Med. 2019;381(21):2020-2031. 64. Ampie L, Woolf EC, Dardis C. Immunotherapeutic
doi: 10.1056/NEJMoa1910231 advancements for glioblastoma. Front Oncol. 2015;5:12.
54. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year doi: 10.3389/fonc.2015.00012
survival with combined nivolumab and Ipilimumab in 65. Weller M, Kaulich K, Hentschel B, et al. Assessment
advanced melanoma. New Engl J Med. 2019;381(16):1535-1546. and prognostic significance of the epidermal growth
doi: 10.1056/nejmoa1910836 factor receptor vIII mutation in glioblastoma patients
treated with concurrent and adjuvant temozolomide
55. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall radiochemotherapy. [published correction appears in Int J
survival with combined nivolumab and Ipilimumab in Cancer. 2016 Aug 15;139(4):E9. doi: 10.1002/ijc.30155].
advanced melanoma. New Engl J Med. 2017;377(14): Int J Cancer. 2014;134(10):2437-2447.
1345-1356.
doi: 10.1002/ijc.28576
doi: 10.1056/nejmoa1709684
66. Powers MV, Jones K, Barillari C, Westwood I,
56. Omuro A, Reardon DA, Sampson JH, et al. Nivolumab van Montfort RL, Workman P. Targeting HSP70: The second
plus radiotherapy with or without temozolomide in potentially druggable heat shock protein and molecular
newly diagnosed glioblastoma: Results from exploratory chaperone? Cell Cycle. 2010;9(8):1542-1550.
phase I cohorts of checkmate 143. Neurooncol Adv.
2022;4(1):vdac025. doi: 10.4161/cc.9.8.11204
doi: 10.1093/noajnl/vdac025 67. Smaglo BG, Aldeghaither D, Weiner LM. The development
of immunoconjugates for targeted cancer therapy. Nat Rev
57. Reardon DA, Kim TM, Frenel J, et al. Treatment with Clin Oncol. 2014;11(11):637-648.
pembrolizumab in programmed death ligand 1-positive
recurrent glioblastoma: Results from the multicohort phase doi: 10.1038/nrclinonc.2014.159
1 KEYNOTE‐028 trial. Cancer. 2021;127(10):1620-1629. 68. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of
doi: 10.1002/cncr.33378 chaperone-mediated protein folding in the cytosol. Nat Rev
Mol Cell Biol. 2004;5(10):781-791.
58. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways:
Similarities, differences, and implications of their inhibition. doi: 10.1038/nrm1492
Am J Clin Oncol. 2016;39(1):98-106. 69. Ampie L, Choy W, Lamano JB, Fakurnejad S, Bloch O,
doi: 10.1097/coc.0000000000000239 Parsa AT. Heat shock protein vaccines against glioblastoma:
From bench to bedside. J Neuro Oncol. 2015;123(3):441-448.
59. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ,
Parsa AT. Gliomas promote immunosuppression through doi: 10.1007/s11060-015-1837-7
induction of B7-H1 expression in tumor-associated 70. Graner MW, Bigner DD. Chaperone proteins and brain
macrophages. Clin Cancer Res. 2013;19(12):3165-3175. tumors: Potential targets and possible therapeutics. Neuro
doi: 10.1158/1078-0432.ccr-12-3314 Oncol. 2005;7(3):260-278.
60. Moyes KW, Davis A, Hoglund V, et al. Effects of tumor doi: 10.1215/S1152851704001188
grade and dexamethasone on myeloid cells in patients with 71. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens
glioma. OncoImmunology. 2018;7(11):e1507668. of chemically induced sarcomas of inbred mice. Proc Natl
doi: 10.1080/2162402x.2018.1507668 Acad Sci U S A. 1986;83(10):3407-3411.
61. Abikenari M, Schonfeld E, Choi J, Kim LH, Lim M. Revisiting doi: 10.1073/pnas.83.10.3407
glioblastoma classification through an immunological lens: 72. Ullrich SJ, Robinson EA, Law LW, Willingham M, Appella E.
A narrative review. Glioma. 2024;7(2):3-9. A mouse tumor-specific transplantation antigen is a
heat shock-related protein. Proc Natl Acad Sci U S A.
doi: 10.4103/glioma.glioma_4_24
1986;83(10):3121-3125.
62. Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death
ligand 1 expression and tumor-infiltrating lymphocytes in doi: 10.1073/pnas.83.10.3121
glioblastoma. Neuro Oncol. 2014;17(8):1064-1075. 73. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R,

Volume 2 Issue 4 (2025) 141 doi: 10.36922/mi.5075